Jan 30 (Reuters) - India's Dr Lal Path Labs (DLPA.NS), opens new tab reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its ...
Earnings call Dr. Lal PathLabs reported 10.7% YoY revenue growth and 19.3% PAT growth in Q3 FY25, despite no price increases. The company is executing a multi-pronged strategy of geographic expansion, ...
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider... 23 Apr, 2026 \| 06:13pm • So ...
Stocks to buy for short term: Market benchmarks the Sensex and the Nifty 50 clocked a healthy gain of 1.6 per cent for the week ended November 14, driven by hopes of an India-US trade deal amid better ...
Bengaluru: Dr. Lal Path Labs reported a lower third-quarter profit on Friday after taking a one-time charge linked to India's new labour code, despite strong demand for its bundled test packages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results